Health
Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial – The Lancet
Lubiprostone was well tolerated and reduced the levels of liver enzymes in patients
with NAFLD and constipation. Further studies are necessary to better define the efficacy
and tolerability of lubiprostone in patients with NAFLD without constipation.
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2020 Elsevier Inc. except certain content provided by third parties.
Privacy Policy Terms and Conditions…
-
General22 hours agoFederal government funding extends cohealth GP services until July 2026
-
Business23 hours agoWhat I’d buy if I had to invest $20,000 in ASX 200 shares before the weekend
-
General6 hours agoMildura man given 28 years to pay $73,000 in unpaid fines and tolls
-
General9 hours agoAustralia’s race to rewire the country amid a global transmission boom is not unique